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Abstract: In this study, the diabetogenic effects of long term Ochratoxin A (OTA) administration in
rats were investigated, and its role in the etiology of diabetes mellitus (DM) was examined utilizing
42 female Wistar rats for these purposes. The rats were divided into three different study and control
groups according to the duration of the OTA administration. The rats received 45 µg OTA daily in
their feed for 6, 9 and 24 weeks, respectively. Three control groups were also used for the same time
periods. Blood and pancreatic tissue samples were collected during the necropsy at the end of the 6, 9
and 24 weeks. The plasma values of insulin, glucagon and glucose were determined for the study
and control groups. Pancreatic lesions were evaluated via histopathological examination and insulin
and glucagon expression in these lesions was subsequently determined using immunohistochemical
methods. Statistically significant decreases in insulin levels were observed, in contrast to increases
in blood glucagon and glucose levels. Histopathological examinations revealed slight to moderate
degeneration in Langerhans islet cells in all OTA-treated groups. Immunohistochemistry of pancreatic
tissue revealed decreased insulin and increased glucagon expression. This study demonstrated that
OTA may cause pancreatic damage in the Langerhans islet and predispose rats to DM.
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1. Introduction
Ochratoxin A (OTA) is a mycotoxin that naturally occurs as a fungal metabolite and is the most
toxic product of Aspergillus ochraceus and Penicillium verrucosum [1]. Its widespread occurrence in
human and animal food in conjunction with some preliminary cytotoxic and carcinogenic data suggest
a possible role for dietary OTA in the development of various organ damage and the occurrence of
different tumors [2–5]. In addition to carcinogenic, mutagenic and cytotoxic effects, OTA is also known
to lead to a decrease in food intake and body weight gain [6]. OTA has been shown to be nephrotoxic,
immunotoxic and teratogenic to a variety of animal species [7]. It is a ubiquitous mycotoxin produced
by fungi in improperly stored food products. Various commodities including corn, peanuts, wheat,
maize, rye, barley, coffee beans, flour, rice, spices, bread and animal feed may contain OTA. The highest
amounts of OTA in food of plant origin were found mainly in Eastern Europe [8–12].
Diabetes mellitus (DM) is an autoinflammatory syndrome that is a collection of many disorders
such as hyperglycemia, dyslipidemia, insulin resistance, impaired beta-cell functioning, and insulin
secretion [13–16]. DM is associated with disturbance of carbohydrate, fat, and protein metabolism
resulting from defects in insulin secretion, insulin action, or both [17]. It is considered to be among the
major life-threatening diseases worldwide, particularly in developing countries [13–16]. DM is one of
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the most crippling diseases that humankind has ever had to deal with, and its prevalence has risen
dramatically over the past two decades [18]. Currently, there are over 150 million diabetics worldwide,
and this is likely to increase to 300 million or more by the year 2025 due to increased sedentary lifestyle,
consumption of energy-rich diet, and obesity [19].
There are few studies investigating the diabetogenic effects of OTA, the extent of which is far
beyond clear. In particular, increased DM incidence in animals necessitates the clarification of any
possible relation between OTA consumption and occurrence of DM. The design of this study was
based on the increased incidence of OTA in contaminated foods and DM in underdeveloped countries,
which indicates possible relations between OTA and diabetes. The aim of this study was to examine
OTA toxicity in the pancreas and the possible diabetogenic effects of this toxication in a rat model.
2. Results
All pancreases had normal gross appearance during necropsy in all groups. Histopathological
examinations of rats revealed vacuolization, megalocytosis and karyomegaly in some islets of
Langerhans in the OTA-treated groups (OTA6, OTA9 and OTA24) while no pathological lesions
were observed in the control groups (Ctrl6, Ctrl9 and Ctrl24) (Figure 1A,D).
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decreased insulin; and (F) increased glucagon expression, streptavidin biotin peroxidase method, bar 
= 50 μm. 
Marked increases were observed in blood glucose and glucagon levels in contrast to decreases 
in insulin levels in the study groups compared to the control groups in 6, 9 and 24-week study 
periods. Statistical analysis results of plasma glucose, insulin and glucagon levels are shown in 
Figures 2–4. Statistically significant differences were observed in all study periods between study and 
control groups. This study showed that OTA causes damage in endocrine pancreatic function, even 
during a six-week exposure period.  
Figure 1. Histopathological and immunohistochemical appearance of the pancreas after a 24-week
period. (A) normal histology, Hematoxylin and Eosin; (B) severe insulin; and (C) glucagon
immunoexpression in the control group, streptavidin biotin peroxidase method; (D) degenerative
and karyomegalic cells in the Langerhans islet (indicated by the arrows), Hematoxylin and Eosin;
(E) decreased insulin; and (F) increased glucagon expression, streptavidin biotin peroxidase method,
bar = 50 µm.
Marked increases were observed in blood glucose and glucagon levels in contrast to decreases in
insulin levels in the study groups compared to the control groups in 6, 9 and 24-week study periods.
Statistical analysis results of plasma glucose, insulin and glucagon levels are shown in Figures 2–4.
Statistically significant differences were observed in all study periods between study and control
groups. This study showed that OTA causes damage in endocrine pancreatic function, even during a
six-week exposure period.
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Figure 2. Statistical analysis of plasma glucose levels in the study and control groups. Statistically
significant increases were observed in the study group results when compared to the same periods
in the control groups (p = 0.009 in OTA6 and Ctrl6; p = 0.048 in OTA9 and Ctrl9; p = 0.007 in OTA24
and Ctrl24).
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Figure 3. Statistical analysis of insulin levels in the study and control groups. Statistically significant
decreases were observed in the study group results when compared to the same periods in the control
groups (p = 0.048 in OTA6 and Ctrl6; p = 0.010 in OTA9 and Ctrl9; p = 0.035 in OTA24 and Ctrl24).
The immunohistochemical examinations showed that the insulin-secreting cells were localized in
the central area of the islets of Langerhans. Marked insulin secretion was observed in the control groups,
and the OTA treatment caused a slight to moderate decrease in the number of insulin-secreting cells
together with the degree of insulin expression in some Langerhans islets. Furthermore, the decrease in
insulin expression is augmented with the increased duration of OTA exposure (Figure 1B,E).
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Figure 4. Statistical analysis of plasma glucagon levels in the study and control groups. Statistically
significant increases were observed in the study group results when compared to the same periods
in the control groups (p = 0.007 in OTA6 and Ctrl6; p = 0.035 in OTA9 and Ctrl9; p = 0.004 in OTA24
and Ctrl24).
Similar levels of glucagon expression were observed in the control groups during the study,
whereas a slight increase occurred in the OTA-treated groups (Figure 1C,F). However, glucagon
positive cells were decreased with the increased duration of OTA exposure. The results of the statistical
analysis of the numbers of insulin and glucagon expressing cells are shown in Figures 5 and 6.
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Figure 6. Statistical analysis of glucagon positive cell percentages in the groups. Statistically significant
increases were seen in the study group results compared to the same period in the control groups
(p < 0.001 in OTA6 and Ctrl6; p = 0.025 in OTA9 and Ctrl9; p = 0.048 in OTA24 and Ctrl24).
3. Discussion
OTA toxication and DM are increasing problems in both human and animal health. There appears
to be a link between OTA toxication and DM, as both are related to food consumption. A few studies
have reported OTA as the possible cause of endocrine pancreas problems, but the diabetogenic effects
of OTA are unclear. The purpose of this study was to examine OTA toxicity in the pancreas and the
possible diabetogenic effects of this toxication in a rat model.
DM is a common illness with high morbidity and an early mortality rate, causing vascular, renal,
retinal, or neuropathic disorders in the long term as well as acute metabolic complications [20]. Diet
along with lifestyle modification is believed to play an important role in the management of this
disease [21,22]. Polydipsia and polyphagia are the most common symptoms of diabetes [17]. OTA
is a ubiquitous mycotoxin produced by the fungi of improperly stored food products [23]. Because
both OTA-related toxicity and DM are food intake-related diseases, the idea of any possible relation
between these conditions was the main objective of this study.
There is little knowledge about the relationships between mycotoxins and DM [24–26]. These
authors reported increases in glucose levels after mycotoxin exposure in rats and chickens. Similar
increases in blood glucose levels were observed in OTA-treated groups in this study. However, there
is no report detailing pathological and histopathological findings in OTA toxication. This is the first
study on the effects of OTA on the pancreas in a rat model.
Suseela et al., 1986, reported increased glucose and decreased insulin levels following mycotoxin
administration in rats [26]. Subramanian et al., 1985, also reported similar results in calves after OTA
exposure [25]. In a recent study, after 30 days of OTA exposure, liver and kidney damages were also
reported in addition to increases in blood glucose levels [27]. The results of our study are in agreement
with previous studies revealing OTA as the cause of increases in blood glucose and glucagon levels, as
well as decreases in blood insulin levels in groups that are administered OTA-contaminated food for
all of the given time periods.
Changes in blood glucose levels as a result of OTA exposure have been reported in pigs [28–31],
rabbits [32] and rats [27,33]. Studies with pigs on blood glucose levels following OTA toxication are
contradictory [28–31]. Decreased blood glucose levels were observed in rabbits fed with 1 and 2 ppm
OTA-contaminated food after three weeks and, at week 8, blood glucose levels were half those of
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the control group [32]. These seemingly contradictory and inconclusive results could be related to
the wide range of OTA doses used in these studies and the exposure periods as well as the possible
species-specific effect of OTA exposure. On the other hand, there have been two studies reporting
that OTA can cause increases in blood glucose levels in rats. In the first study, OTA (100 g/rat/day)
was given orally by gavage for eight weeks; it was found that blood glucose levels increased while
insulin levels decreased [33]. Similarly, in the second study, 30 days of OTA treatment resulted in
blood glucose level increases [27]. As both studies indicated that OTA is a possible diabetogenic toxin,
its direct effects on the pancreas and pancreatic cells were revealed for the first time in addition to
its effects on blood glucose, insulin and glucagon levels. In fact, a relationship between OTA and
blood glucagon levels and a marked glucagon decrease after six weeks of OTA exposure were also first
reported in this study. In addition to all these new findings, the diabetogenic effects of OTA exposure
were first observed in a time dependent manner, from six weeks to 24 weeks. Furthermore, this is the
first study showing that OTA does not only alter blood glucose and insulin levels in rats, but also leads
to increases in blood glucagon levels and causes pancreatic lesions.
A decrease in insulin secretion or diminished insulin activity causes a rise in glucagon
concentrations and pancreatic expression of the hormone [32]. Although there are reports on insulin
and glucose levels in mycotoxin-administered rats, there is no knowledge regarding glucagon levels
in OTA-related rat studies in the literature. This is the first study to examine glucagon levels in a
rat model of OTA toxication together with blood results obtained by ELISA and pancreas results by
immunohistochemistry. In agreement with a study by Ozmen et al. [34], the results of this study
demonstrate that OTA causes an increase in blood glucagon levels and expression in the pancreas. The
cause of this result may be related to decreased insulin secretion and a relative increase in glucagon
secreted cells. Very sensitive insulin and glucagon ELISA kits were used, and assay results supported
the immunohistochemical findings.
OTA can cause degenerative, necrotic and cancerogenic effects in cells. Karyomegaly is the most
common and characteristic pathological finding in liver and kidney cells after OTA exposure [35].
However, there is no knowledge of pancreatic cell reactions after OTA treatment. This study
demonstrates that OTA causes degeneration, karyomegaly and megalocytosis in pancreatic cells.
Insulin secreted cells were found to be more sensitive to OTA toxication in this study, compared to
glucagon secreted cells.
DM is one of the most challenging metabolic disorders, as it cannot be cured but must only be
managed. Numerous people and animals suffer from DM throughout the world [36,37]. Numerous
studies have been performed on the etiology, pathogenesis and treatment of this significant and
common disease. OTA is the main cause of the various organ and tissue damage in exposed humans
and animals [2–5,27]. The results of this study suggest that OTA may also be involved in diabetogenic
agents. In this study, none of our three control groups exhibited any abnormality in either plasma
levels or pancreatic tissues, therefore all of the abnormal plasma and tissue results can be attributed to
OTA toxicity.
The main potential flaw of the study was the small number of rats used. However, because of
the long duration and the fact that there were six groups, the number of rats was reduced. The other
possible limitation may be that only immunohistochemistry was used for molecular analysis. Further
and expanded research may be planned for better evaluation. Because this is the first extensive study
of its kind, it will be a basis for further such studies.
The results of this study have demonstrated that OTA can have toxic effects on the endocrine
pancreas in a rat model. Although toxicity can be observed even in a six-week period of exposure,
longer term OTA exposure may be more effective. Our results demonstrated that OTA damage
in the exocrine pancreas may be an etiologic factor for DM in humans and animals. In addition,
our study suggests a possible relationship between the OTA exposure period and the severity of
pancreatic damage. This is the first detailed research on diabetogenic effects. Further and expanded
studies are needed for the clarification of the relationship between OTA and DM.
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4. Materials and Methods
4.1. Animals, Housing Conditions and Experimental Procedures
In this study, pancreas and plasma samples were collected from our previous study as approved
by Akdeniz University Local Animal Research Committee (No: 2011.12.02). The study was performed
in accordance with the National Institutes of Health Guidelines for the Care and Handling of Animals.
Rats were kept in the experimental animal laboratory of Akdeniz University. This laboratory has an
international accreditation certificate attesting suitable conditions for such work.
Female Wistar rats (16 weeks old), from the Akdeniz University Animal Experiment Unit, were
housed on sawdust bedding in groups of four to five in polycarbonate cages with stainless steel
covers. Room temperature was maintained at 22 ± 2 ◦C with a relative humidity of 55 ± 10% and
a day/night cycle of 12 h. Rats were given a diet (20 g/rat/day) in stainless steel containers, and
water was available ad libitum. The physical condition of each rat was assessed daily for any obvious
clinical signs.
Forty-two rats, weighing 125–150 g at the start of the experiment, were randomly allocated into
six groups (n = 7). The experimental groups (OTA6, 9, 24) were given an OTA-contaminated diet for
6, 9 and 24 weeks, respectively. The control groups (Ctrl6, 9 and 24) were given the standardized
powdered rat diet for the same period of time. The feeding methods and OTA doses were essentially
the same as those described by Mor et al. (2014). Rats were given 3 mg OTA kg−1 food and the initial
OTA dose was approximately 45 g OTA/rat/day.
At the end of the study periods, blood (1–1.5 mL) was collected from a tail vein under ether
anesthesia, centrifuged immediately and the plasma stored at −40◦C. After blood collection, rats were
euthanized to collect tissue samples.
4.2. Plasma Insulin, Glucagon and Glucose Determination
Plasma glucose levels were analyzed using an Autoanalyzer (Gesan chem 200 Gesan Production
srl, Campobello, Italy). Plasma insulin and glucagon levels were analyzed using an ultrasensitive rat
insulin ELISA kit (Cat. No: Rab 3050; Sigma Aldich Chemie GmBH, St. Louis, MO, USA) and glucagon
ELISA kit (Cat. No: Rab 0202; Sigma Aldich Chemie GmBH, St. Louis, MO, USA) with a multiplate
ELISA reader (EPOCH microplate reader; Bio-Tek, Inc., Winooski, VT, USA). Results are expressed as
mg/dL for glucose, µIU/mL for insulin and pg/mL for glucagon.
The minimum detectable amount (MDA) for rat insulin was 5 µIU/mL. Recovery was performed
by spiking plasma samples with rat insulin (10–50 µIU/mL) and the recovery was 67–129% with an
average of 94.68%.
The minimum detectable amount (MDA) of glucagon was 6.37 pg/mL. The recovery of glucagon
spiked to levels throughout the range of the assay in rat plasma. The mean recovery was 93% and the
range was 86–101%.
The methods used for plasma insulin and glucagon levels were in accordance with the
manufacturer’s instructions.
4.3. Histological Examination
During the necropsy, pancreatic tissue samples were collected and fixed in 10% buffered formalin.
After routine processing, tissues were embedded in paraffin and sectioned to a thickness of 5 µm.
Tissue sections were stained with hematoxylin-eosin and examined microscopically.
Pancreas samples were then immunostained with insulin antiserum (Anti-insulin + Proinsulin
antibody, [D6D4] Abcam (ab8304), 1/100 dilution; Abcam, Cambridge, UK) and glucagon antiserum
(antiglucagon antibody, Abcam (ab8055), 1/100 dilution; Abcam, Cambridge, UK) according to
the manufacturer’s instructions. All of the slides were analyzed for hormone positivity and a
semi-quantitative analysis was carried out as detailed later. The overall number of positive cells
in 1 high-power field (40×), as well as the number of cells per islet that were positive for each hormone,
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were noted and compared with normal pancreatic tissue counts. An attempt was made to quantify
the percentage positivity of each hormone-producing cell in each of the islets. All islets in at least 5
high-power fields were selected, the total number of nuclei in each islet was counted, and the average
number of nuclei/islet was calculated. The average percentage of cells positive for each hormone was
then calculated for the islets. Morphometric evaluation was made by using the Database Manual Cell
Sens Life Science Imaging Software System (Olympus Corporation, Tokyo, Japan).
4.4. Statistical Analysis
One-way ANOVA analysis of variance tests were used to determine whether there were any
significant differences between the groups with regard to their blood glucose, glucagon and insulin
values. In the determination of differences between groups, the Bonferroni Dunn test was used.
Calculations were made using the MiniTab (2011) program pack.
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